Tight junction proteins: From barrier to tumorigenesis

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 41-48

  Runkle, E Aaron ^a   Mu, David ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Claudin; Metastasis; Occludin; Tight junction

Indexed keywords

CLAUDIN; JUNCTIONAL ADHESION MOLECULE; MARVELD3; OCCLUDIN; TIGHT JUNCTION PROTEIN; TRICELLULIN; UNCLASSIFIED DRUG; ZO PROTEIN;

CANCER GENETICS; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; METASTASIS; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; STEM CELL; TIGHT JUNCTION; TUMOR GENE;

EID: 84880044601     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.038     Document Type: Review

References (133)

1. Mineta K., Yamamoto Y., Yamazaki Y., Tanaka H., Tada Y., Saito K., Tamura A., Igarashi M., Endo T., Takeuchi K., Tsukita S. Predicted expansion of the claudin multigene family. FEBS Lett. 2011, 585:606-612.
2. Farquhar M.G., Palade G.E. Junctional complexes in various epithelia. J. Cell Biol. 1963, 17:375-412.
3. van Meer G., Gumbiner B., Simons K. The tight junction does not allow lipid molecules to diffuse from one epithelial cell to the next. Nature 1986, 322:639-641.
4. Balda M.S., Matter K. Tight junctions and the regulation of gene expression. Biochim. Biophys. Acta 2009, 1788:761-767.
5. Balda M.S., Garrett M.D., Matter K. The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. J. Cell Biol. 2003, 160:423-432.
6. Gumbiner B., Lowenkopf T., Apatira D. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc. Natl. Acad. Sci. USA 1991, 88:3460-3464.
7. Haskins J., Gu L., Wittchen E.S., Hibbard J., Stevenson B.R. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J. Cell Biol. 1998, 141:199-208.
8. Jesaitis L.A., Goodenough D.A. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the Drosophila discs-large tumor suppressor protein. J. Cell Biol. 1994, 124:949-961.
9. Stevenson B.R., Siliciano J.D., Mooseker M.S., Goodenough D.A. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell Biol. 1986, 103:755-766.
10. Woods D.F., Bryant P.J. ZO-1, DlgA and PSD-95/SAP90: homologous proteins in tight, septate and synaptic cell junctions. Mech. Dev. 1993, 44:85-89.
11. Van Itallie C.M., Aponte A., Tietgens A.J., Gucek M., Fredriksson K., Anderson J.M. The N- and C-termini of ZO-1 are surrounded by distinct proteins and functional protein networks. J. Biol. Chem. 2013.
12. Fanning A.S., Little B.P., Rahner C., Utepbergenov D., Walther Z., Anderson J.M. The unique-5 and -6 motifs of ZO-1 regulate tight junction strand localization and scaffolding properties. Mol. Biol. Cell 2007, 18:721-731.
13. Li Y., Fanning A.S., Anderson J.M., Lavie A. Structure of the conserved cytoplasmic C-terminal domain of occludin: identification of the ZO-1 binding surface. J. Mol. Biol. 2005, 352:151-164.
14. Sundstrom J.M., Tash B.R., Murakami T., Flanagan J.M., Bewley M.C., Stanley B.A., Gonsar K.B., Antonetti D.A. Identification and analysis of occludin phosphosites: a combined mass spectrometry and bioinformatics approach. J. Proteome Res. 2009, 8:808-817.
15. Itoh M., Furuse M., Morita K., Kubota K., Saitou M., Tsukita S. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J. Cell Biol. 1999, 147:1351-1363.
16. Ebnet K., Schulz C.U., Meyer Zu Brickwedde M.K., Pendl G.G., Vestweber D. Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. J. Biol. Chem. 2000, 275:27979-27988.
17. McNeil E., Capaldo C.T., Macara I.G. Zonula occludens-1 function in the assembly of tight junctions in Madin-Darby canine kidney epithelial cells. Mol. Biol. Cell 2006, 17:1922-1932.
18. Umeda K., Matsui T., Nakayama M., Furuse K., Sasaki H., Furuse M., Tsukita S. Establishment and characterization of cultured epithelial cells lacking expression of ZO-1. J. Biol. Chem. 2004, 279:44785-44794.
19. Hernandez S., Chavez Munguia B., Gonzalez-Mariscal L. ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture. Exp. Cell Res. 2007, 313:1533-1547.
20. Umeda K., Ikenouchi J., Katahira-Tayama S., Furuse K., Sasaki H., Nakayama M., Matsui T., Tsukita S., Furuse M. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006, 126:741-754.
21. Katsuno T., Umeda K., Matsui T., Hata M., Tamura A., Itoh M., Takeuchi K., Fujimori T., Nabeshima Y., Noda T., Tsukita S. Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol. Biol. Cell 2008, 19:2465-2475.
22. Xu J., Kausalya P.J., Phua D.C., Ali S.M., Hossain Z., Hunziker W. Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development. Mol. Cell. Biol. 2008, 28:1669-1678.
23. Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 1993, 123:1777-1788.
24. Balda M.S., Whitney J.A., Flores C., Gonzalez S., Cereijido M., Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J. Cell Biol. 1996, 134:1031-1049.
25. Saitou M., Furuse M., Sasaki H., Schulzke J.D., Fromm M., Takano H., Noda T., Tsukita S. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 2000, 11:4131-4142.
26. Yu A.S., McCarthy K.M., Francis S.A., McCormack J.M., Lai J., Rogers R.A., Lynch R.D., Schneeberger E.E. Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells. Am J Physiol. Cell Physiol. 2005, 288:C1231-1241.
27. Phillips B.E., Cancel L., Tarbell J.M., Antonetti D.A. Occludin independently regulates permeability under hydrostatic pressure and cell division in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2008, 49:2568-2576.
28. Murakami T., Felinski E.A., Antonetti D.A. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 2009, 284:21036-21046.
29. Murakami T., Frey T., Lin C., Antonetti D.A. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 2012.
30. Shen L., Turner J.R. Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis. Mol. Biol. Cell 2005, 16:3919-3936.
31. Marchiando A.M., Shen L., Graham W.V., Weber C.R., Schwarz B.T., Austin J.R., Raleigh D.R., Guan Y., Watson A.J., Montrose M.H., Turner J.R. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J. Cell Biol. 2010, 189:111-126.
32. Tsukita S., Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players?. Trends Cell Biol. 1999, 9:268-273.
33. Furuse M., Sasaki H., Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol. 1999, 147:891-903.
34. Piontek J., Winkler L., Wolburg H., Muller S.L., Zuleger N., Piehl C., Wiesner B., Krause G., Blasig I.E. Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J. 2008, 22:146-158.
35. Furuse M., Hata M., Furuse K., Yoshida Y., Haratake A., Sugitani Y., Noda T., Kubo A., Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 2002, 156:1099-1111.
36. Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., Furuse M., Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 2003, 161:653-660.
37. Gow A., Southwood C.M., Li J.S., Pariali M., Riordan G.P., Brodie S.E., Danias J., Bronstein J.M., Kachar B., Lazzarini R.A. CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell 1999, 99:649-659.
38. Konrad M., Hou J., Weber S., Dotsch J., Kari J.A., Seeman T., Kuwertz-Broking E., Peco-Antic A., Tasic V., Dittrich K., Alshaya H.O., von Vigier R.O., Gallati S., Goodenough D.A., Schaller A. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J. Am. Soc. Nephrol. 2008, 19:171-181.
39. Konrad M., Schaller A., Seelow D., Pandey A.V., Waldegger S., Lesslauer A., Vitzthum H., Suzuki Y., Luk J.M., Becker C., Schlingmann K.P., Schmid M., Rodriguez-Soriano J., Ariceta G., Cano F., Enriquez R., Juppner H., Bakkaloglu S.A., Hediger M.A., Gallati S., Neuhauss S.C., Nurnberg P., Weber S. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am. J. Hum. Genet. 2006, 79:949-957.
40. Kitajiri S., Miyamoto T., Mineharu A., Sonoda N., Furuse K., Hata M., Sasaki H., Mori Y., Kubota T., Ito J., Furuse M., Tsukita S. Compartmentalization established by claudin-11-based tight junctions in stria vascularis is required for hearing through generation of endocochlear potential. J. Cell Sci. 2004, 117:5087-5096.
41. Ben-Yosef T., Belyantseva I.A., Saunders T.L., Hughes E.D., Kawamoto K., Van Itallie C.M., Beyer L.A., Halsey K., Gardner D.J., Wilcox E.R., Rasmussen J., Anderson J.M., Dolan D.F., Forge A., Raphael Y., Camper S.A., Friedman T.B. Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degeneration. Hum. Mol. Genet. 2003, 12:2049-2061.
42. Liu Y., Nusrat A., Schnell F.J., Reaves T.A., Walsh S., Pochet M., Parkos C.A. Human junction adhesion molecule regulates tight junction resealing in epithelia. J. Cell Sci. 2000, 113(Pt 13):2363-2374.
43. Mandell K.J., McCall I.C., Parkos C.A. Involvement of the junctional adhesion molecule-1 (JAM1) homodimer interface in regulation of epithelial barrier function. J. Biol. Chem. 2004, 279:16254-16262.
44. Mandell K.J., Babbin B.A., Nusrat A., Parkos C.A. Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on beta1 integrins and Rap1 activity. J. Biol. Chem. 2005, 280:11665-11674.
45. Vetrano S., Rescigno M., Cera M.R., Correale C., Rumio C., Doni A., Fantini M., Sturm A., Borroni E., Repici A., Locati M., Malesci A., Dejana E., Danese S. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 2008, 135:173-184.
46. Rehder D., Iden S., Nasdala I., Wegener J., Brickwedde M.K., Vestweber D., Ebnet K. Junctional adhesion molecule-a participates in the formation of apico-basal polarity through different domains. Exp. Cell Res. 2006, 312:3389-3403.
47. Ebnet K., Suzuki A., Horikoshi Y., Hirose T., Meyer Zu Brickwedde M.K., Ohno S., Vestweber D. The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM). EMBO J. 2001, 20:3738-3748.
48. Itoh M., Sasaki H., Furuse M., Ozaki H., Kita T., Tsukita S. Junctional adhesion molecule (JAM) binds to PAR-3: a possible mechanism for the recruitment of PAR-3 to tight junctions. J. Cell Biol. 2001, 154:491-497.
49. Laukoetter M.G., Nava P., Lee W.Y., Severson E.A., Capaldo C.T., Babbin B.A., Williams I.R., Koval M., Peatman E., Campbell J.A., Dermody T.S., Nusrat A., Parkos C.A. JAM-A regulates permeability and inflammation in the intestine in vivo. J. Exp. Med. 2007, 204:3067-3076.
50. Ikenouchi J., Furuse M., Furuse K., Sasaki H., Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J. Cell Biol. 2005, 171:939-945.
51. Riazuddin S., Ahmed Z.M., Fanning A.S., Lagziel A., Kitajiri S., Ramzan K., Khan S.N., Chattaraj P., Friedman P.L., Anderson J.M., Belyantseva I.A., Forge A., Friedman T.B. Tricellulin is a tight-junction protein necessary for hearing. Am. J. Hum. Genet. 2006, 79:1040-1051.
52. Chishti M.S., Bhatti A., Tamim S., Lee K., McDonald M.L., Leal S.M., Ahmad W. Splice-site mutations in the TRIC gene underlie autosomal recessive nonsyndromic hearing impairment in Pakistani families. J. Hum. Genet. 2008, 53:101-105.
53. Ikenouchi J., Sasaki H., Tsukita S., Furuse M. Loss of occludin affects tricellular localization of tricellulin. Mol. Biol. Cell 2008, 19:4687-4693.
54. Krug S.M., Amasheh S., Richter J.F., Milatz S., Gunzel D., Westphal J.K., Huber O., Schulzke J.D., Fromm M. Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability. Mol. Biol. Cell 2009, 20:3713-3724.
55. Steed E., Rodrigues N.T., Balda M.S., Matter K. Identification of MarvelD3 as a tight junction-associated transmembrane protein of the occludin family. BMC Cell Biol. 2009, 10:95.
56. Raleigh D.R., Marchiando A.M., Zhang Y., Shen L., Sasaki H., Wang Y., Long M., Turner J.R. Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions. Mol. Biol. Cell 2010, 21:1200-1213.
57. Timmann C., Thye T., Vens M., Evans J., May J., Ehmen C., Sievertsen J., Muntau B., Ruge G., Loag W., Ansong D., Antwi S., Asafo-Adjei E., Nguah S.B., Kwakye K.O., Akoto A.O., Sylverken J., Brendel M., Schuldt K., Loley C., Franke A., Meyer C.G., Agbenyega T., Ziegler A., Horstmann R.D. Genome-wide association study indicates two novel resistance loci for severe malaria. Nature 2012, 489:443-446.
58. Cording J., Berg J., Kading N., Bellmann C., Tscheik C., Westphal J.K., Milatz S., Gunzel D., Wolburg H., Piontek J., Huber O., Blasig I.E. In tight junctions, claudins regulate the interactions between occludin, tricellulin and marvelD3, which, inversely, modulate claudin oligomerization. J. Cell Sci. 2013, 126:554-564.
59. Balda M.S., Matter K. The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression. EMBO J. 2000, 19:2024-2033.
60. Sourisseau T., Georgiadis A., Tsapara A., Ali R.R., Pestell R., Matter K., Balda M.S. Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol. Cell. Biol. 2006, 26:2387-2398.
61. Lima W.R., Parreira K.S., Devuyst O., Caplanusi A., N'Kuli F., Marien B., Van Der Smissen P., Alves P.M., Verroust P., Christensen E.I., Terzi F., Matter K., Balda M.S., Pierreux C.E., Courtoy P.J. ZONAB promotes proliferation and represses differentiation of proximal tubule epithelial cells. J. Am. Soc. Nephrol. 2010, 21:478-488.
62. R. Kaseda, M. Hosojima, H. Sato, A. Saito, Role of megalin and cubilin in the metabolism of vitamin D(3), Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 15(1) (2011) 14-17.
63. Islas S., Vega J., Ponce L., Gonzalez-Mariscal L. Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Exp. Cell Res. 2002, 274:138-148.
64. Traweger A., Fuchs R., Krizbai I.A., Weiger T.M., Bauer H.C., Bauer H. The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B. J. Biol. Chem. 2003, 278:2692-2700.
65. Betanzos A., Huerta M., Lopez-Bayghen E., Azuara E., Amerena J., Gonzalez-Mariscal L. The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. Exp. Cell Res. 2004, 292:51-66.
66. Huerta M., Munoz R., Tapia R., Soto-Reyes E., Ramirez L., Recillas-Targa F., Gonzalez-Mariscal L., Lopez-Bayghen E. Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc. Mol. Biol. Cell 2007, 18:4826-4836.
67. Tapia R., Huerta M., Islas S., Avila-Flores A., Lopez-Bayghen E., Weiske J., Huber O., Gonzalez-Mariscal L. Zona occludens-2 inhibits cyclin D1 expression and cell proliferation and exhibits changes in localization along the cell cycle. Mol. Biol. Cell 2009, 20:1102-1117.
68. Gonzalez-Mariscal L., Tapia R., Huerta M., Lopez-Bayghen E. The tight junction protein ZO-2 blocks cell cycle progression and inhibits cyclin D1 expression. Ann. NY Acad. Sci. 2009, 1165:121-125.
69. Traweger A., Lehner C., Farkas A., Krizbai I.A., Tempfer H., Klement E., Guenther B., Bauer H.C., Bauer H. Nuclear Zonula occludens-2 alters gene expression and junctional stability in epithelial and endothelial cells. Differentiation 2008, 76:99-106.
70. Schulzke J.D., Gitter A.H., Mankertz J., Spiegel S., Seidler U., Amasheh S., Saitou M., Tsukita S., Fromm M. Epithelial transport and barrier function in occludin-deficient mice. Biochim. Biophys. Acta 2005, 1669:34-42.
71. Runkle E.A., Sundstrom J.M., Runkle K.B., Liu X., Antonetti D.A. Occludin localizes to centrosomes and modifies mitotic entry. J. Biol. Chem. 2011, 286:30847-30858.
72. Jayagopal A., Yang J.L., Haselton F.R., Chang M.S. Tight junction-associated signaling pathways modulate cell proliferation in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2011, 52:588-593.
73. Tamura A., Kitano Y., Hata M., Katsuno T., Moriwaki K., Sasaki H., Hayashi H., Suzuki Y., Noda T., Furuse M., Tsukita S. Megaintestine in claudin-15-deficient mice. Gastroenterology 2008, 134:523-534.
74. Qin W., Ren Q., Liu T., Huang Y., Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013.
75. Elfimova N., Sievers E., Eischeid H., Kwiecinski M., Noetel A., Hunt H., Becker D., Frommolt P., Quasdorff M., Steffen H.M., Nurnberg P., Buttner R., Teufel A., Dienes H.P., Drebber U., Odenthal M. Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. Biochim. Biophys. Acta 1833, 2013:1190-1198.
76. Rastaldi M.P. Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J. Nephrol. 2006, 19:407-412.
77. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006, 172:973-981.
78. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
79. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
80. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 2003, 15:740-746.
81. Valdes F., Alvarez A.M., Locascio A., Vega S., Herrera B., Fernandez M., Benito M., Nieto M.A., Fabregat I. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol. Cancer Res. 2002, 1:68-78.
82. Medici D., Hay E.D., Goodenough D.A. Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition. Mol. Biol. Cell 2006, 17:1871-1879.
83. Wu X., Chen H., Parker B., Rubin E., Zhu T., Lee J.S., Argani P., Sukumar S. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 2006, 66:9527-9534.
84. Ikenouchi J., Matsuda M., Furuse M., Tsukita S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci. 2003, 116:1959-1967.
85. Vincent T., Neve E.P., Johnson J.R., Kukalev A., Rojo F., Albanell J., Pietras K., Virtanen I., Philipson L., Leopold P.L., Crystal R.G., de Herreros A.G., Moustakas A., Pettersson R.F., Fuxe J. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat. Cell Biol. 2009, 11:943-950.
86. Reichert M., Muller T., Hunziker W. The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signaling. J. Biol. Chem. 2000, 275:9492-9500.
87. Masuda R., Semba S., Mizuuchi E., Yanagihara K., Yokozaki H. Negative regulation of the tight junction protein tricellulin by snail-induced epithelial-mesenchymal transition in gastric carcinoma cells. Pathobiology 2010, 77:106-113.
88. Kojima T., Takasawa A., Kyuno D., Ito T., Yamaguchi H., Hirata K., Tsujiwaki M., Murata M., Tanaka S., Sawada N. Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells. Exp. Cell Res. 2011, 317:2288-2298.
89. Li D., Mrsny R.J. Oncogenic Raf-1 disrupts epithelial tight junctions via downregulation of occludin. J. Cell Biol. 2000, 148:791-800.
90. Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J., Nusrat A. Raf 1 represses expression of the tight junction protein occludin via activation of the zinc-finger transcription factor slug. Oncogene 2007, 26:1222-1230.
91. Chen Y., Lu Q., Schneeberger E.E., Goodenough D.A. Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol. Biol. Cell 2000, 11:849-862.
92. Lan M., Kojima T., Osanai M., Chiba H., Sawada N. Oncogenic Raf-1 regulates epithelial to mesenchymal transition via distinct signal transduction pathways in an immortalized mouse hepatic cell line. Carcinogenesis 2004, 25:2385-2395.
93. Xie L., Law B.K., Chytil A.M., Brown K.A., Aakre M.E., Moses H.L. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004, 6:603-610.
94. Wang Z., Mandell K.J., Parkos C.A., Mrsny R.J., Nusrat A. The second loop of occludin is required for suppression of Raf1-induced tumor growth. Oncogene 2005, 24:4412-4420.
95. Harten S.K., Shukla D., Barod R., Hergovich A., Balda M.S., Matter K., Esteban M.A., Maxwell P.H. Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. Mol. Biol. Cell 2009, 20:1089-1101.
96. Osanai M., Murata M., Nishikiori N., Chiba H., Kojima T., Sawada N. Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res. 2006, 66:9125-9133.
97. Osanai M., Murata M., Nishikiori N., Chiba H., Kojima T., Sawada N. Occludin-mediated premature senescence is a fail-safe mechanism against tumorigenesis in breast carcinoma cells. Cancer Sci. 2007, 98:1027-1034.
98. Singh A.B., Sharma A., Dhawan P. Claudin family of proteins and cancer: an overview. J. Oncol. 2010, 2010:541957.
99. Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., Neff J., Washington M.K., Beauchamp R.D. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Invest. 2005, 115:1765-1776.
100. Chao Y.C., Pan S.H., Yang S.C., Yu S.L., Che T.F., Lin C.W., Tsai M.S., Chang G.C., Wu C.H., Wu Y.Y., Lee Y.C., Hong T.M., Yang P.C. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 2009, 179:123-133.
101. Michl P., Barth C., Buchholz M., Lerch M.M., Rolke M., Holzmann K.H., Menke A., Fensterer H., Giehl K., Lohr M., Leder G., Iwamura T., Adler G., Gress T.M. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003, 63:6265-6271.
102. Rangel L.B., Agarwal R., D'Souza T., Pizer E.S., Alo P.L., Lancaster W.D., Gregoire L., Schwartz D.R., Cho K.R., Morin P.J. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin. Cancer Res. 2003, 9:2567-2575.
103. Zhu Y., Brannstrom M., Janson P.O., Sundfeldt K. Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int. J. Cancer 2006, 118:1884-1891.
104. Agarwal R., D'Souza T., Morin P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65:7378-7385.
105. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., Rein A., Sauter G., Kallioniemi O.P., Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22:2021-2033.
106. Dhawan P., Ahmad R., Chaturvedi R., Smith J.J., Midha R., Mittal M.K., Krishnan M., Chen X., Eschrich S., Yeatman T.J., Harris R.C., Washington M.K., Wilson K.T., Beauchamp R.D., Singh A.B. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene 2011, 30:3234-3247.
107. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., Backlund M.G., Yin Y., Khramtsov A.I., Bastein R., Quackenbush J., Glazer R.I., Brown P.H., Green J.E., Kopelovich L., Furth P.A., Palazzo J.P., Olopade O.I., Bernard P.S., Churchill G.A., Van Dyke T., Perou C.M. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
108. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
109. Cardoso W.V., Lu J. Regulation of early lung morphogenesis: questions, facts and controversies. Development 2006, 133:1611-1624.
110. Maeda Y., Dave V., Whitsett J.A. Transcriptional control of lung morphogenesis. Physiol. Rev. 2007, 87:219-244.
111. Kendall J., Liu Q., Bakleh A., Krasnitz A., Nguyen K.C., Lakshmi B., Gerald W.L., Powers S., Mu D. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc. Natl. Acad. Sci. USA 2007, 104:16663-16668.
112. Kwei K.A., Kim Y.H., Girard L., Kao J., Pacyna-Gengelbach M., Salari K., Lee J., Choi Y.L., Sato M., Wang P., Hernandez-Boussard T., Gazdar A.F., Petersen I., Minna J.D., Pollack J.R. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 27:3635-3640.
113. Tanaka H., Yanagisawa K., Shinjo K., Taguchi A., Maeno K., Tomida S., Shimada Y., Osada H., Kosaka T., Matsubara H., Mitsudomi T., Sekido Y., Tanimoto M., Yatabe Y., Takahashi T. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007, 67:6007-6011.
114. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., Lin W.M., Province M.A., Kraja A., Johnson L.A., Shah K., Sato M., Thomas R.K., Barletta J.A., Borecki I.B., Broderick S., Chang A.C., Chiang D.Y., Chirieac L.R., Cho J., Fujii Y., Gazdar A.F., Giordano T., Greulich H., Hanna M., Johnson B.E., Kris M.G., Lash A., Lin L., Lindeman N., Mardis E.R., McPherson J.D., Minna J.D., Morgan M.B., Nadel M., Orringer M.B., Osborne J.R., Ozenberger B., Ramos A.H., Robinson J., Roth J.A., Rusch V., Sasaki H., Shepherd F., Sougnez C., Spitz M.R., Tsao M.S., Twomey D., Verhaak R.G., Weinstock G.M., Wheeler D.A., Winckler W., Yoshizawa A., Yu S., Zakowski M.F., Zhang Q., Beer D.G., Wistuba, Watson M.A., Garraway L.A., Ladanyi M., Travis W.D., Pao W., Rubin M.A., Gabriel S.B., Gibbs R.A., Varmus H.E., Wilson R.K., Lander E.S., Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
115. Maeda Y., Tsuchiya T., Hao H., Tompkins D.H., Xu Y., Mucenski M.L., Du L., Keiser A.R., Fukazawa T., Naomoto Y., Nagayasu T., Whitsett J.A. Kras(G12D) and Nk2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J. Clin. Invest. 2012, 122:4388-4400.
116. Snyder E.L., Watanabe H., Magendantz M., Hoersch S., Chen T.A., Wang D.G., Crowley D., Whittaker C.A., Meyerson M., Kimura S., Jacks T. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol. Cell 2013.
117. Winslow M.M., Dayton T.L., Verhaak R.G., Kim-Kiselak C., Snyder E.L., Feldser D.M., Hubbard D.D., DuPage M.J., Whittaker C.A., Hoersch S., Yoon S., Crowley D., Bronson R.T., Chiang D.Y., Meyerson M., Jacks T. Suppression of lung adenocarcinoma progression by Nk2-1. Nature 2011, 473:101-104.
118. Runkle E.A., Rice S.J., Qi J., Masser D., Antonetti D.A., Winslow M.M., Mu D. Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1). J. Biol. Chem. 2012, 287:28790-28801.
119. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
120. Tsukita S., Yamazaki Y., Katsuno T., Tamura A. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 2008, 27:6930-6938.
121. Szabo I., Kiss A., Schaff Z., Sobel G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol. Histopathol. 2009, 24:1607-1615.
122. Jung J.H., Jung C.K., Choi H.J., Jun K.H., Yoo J., Kang S.J., Lee K.Y. Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas. Pathol. Res. Pract. 2009, 205:409-416.
123. Mann K.M., Ward J.M., Yew C.C., Kovochich A., Dawson D.W., Black M.A., Brett B.T., Sheetz T.E., Dupuy A.J., Australian Pancreatic Cancer Genome I., Chang D.K., Biankin A.V., Waddell N., Kassahn K.S., Grimmond S.M., Rust A.G., Adams D.J., Jenkins N.A., Copeland N.G. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 2012, 109:5934-5941.
124. Alroy J. Ultrastructure of canine urinary bladder carcinoma. Vet. Pathol. 1979, 16:693-701.
125. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
126. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
127. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
128. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
129. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
130. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
131. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
132. Barretina J., Taylor B.S., Banerji S., Ramos A.H., Lagos-Quintana M., Decarolis P.L., Shah K., Socci N.D., Weir B.A., Ho A., Chiang D.Y., Reva B., Mermel C.H., Getz G., Antipin Y., Beroukhim R., Major J.E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T.J., Cibulskis K., Onofrio R.C., Saito T., Shukla N., Lau C., Nelander S., Silver S.J., Sougnez C., Viale A., Winckler W., Maki R.G., Garraway L.A., Lash A., Greulich H., Root D.E., Sellers W.R., Schwartz G.K., Antonescu C.R., Lander E.S., Varmus H.E., Ladanyi M., Sander C., Meyerson M., Singer S. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 2010, 42:715-721.
133. N.Cancer Genome Atlas Research, Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., Yau C., Laird P.W., Ding L., Zhang W., Mills G.B., Kucherlapati R., Mardis E.R., Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.